ATE551336T1 - Substituierte hydantoine - Google Patents

Substituierte hydantoine

Info

Publication number
ATE551336T1
ATE551336T1 AT08786933T AT08786933T ATE551336T1 AT E551336 T1 ATE551336 T1 AT E551336T1 AT 08786933 T AT08786933 T AT 08786933T AT 08786933 T AT08786933 T AT 08786933T AT E551336 T1 ATE551336 T1 AT E551336T1
Authority
AT
Austria
Prior art keywords
compounds
substituted hydantoins
mek2
mek
enzymes
Prior art date
Application number
AT08786933T
Other languages
English (en)
Inventor
Shaoqing Chen
Nicholas Huby
Norman Kong
John Moliterni
Omar Morales
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE551336T1 publication Critical patent/ATE551336T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
AT08786933T 2007-08-16 2008-08-06 Substituierte hydantoine ATE551336T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95614507P 2007-08-16 2007-08-16
PCT/EP2008/060326 WO2009021887A1 (en) 2007-08-16 2008-08-06 Substituted hydantoins

Publications (1)

Publication Number Publication Date
ATE551336T1 true ATE551336T1 (de) 2012-04-15

Family

ID=39830023

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08786933T ATE551336T1 (de) 2007-08-16 2008-08-06 Substituierte hydantoine

Country Status (12)

Country Link
US (1) US7557221B2 (de)
EP (1) EP2188276B1 (de)
JP (1) JP2010536723A (de)
KR (1) KR101147583B1 (de)
CN (1) CN101778839A (de)
AT (1) ATE551336T1 (de)
AU (1) AU2008288556A1 (de)
BR (1) BRPI0815180A2 (de)
CA (1) CA2695956A1 (de)
ES (1) ES2383927T3 (de)
MX (1) MX2010001581A (de)
WO (1) WO2009021887A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
MX368257B (es) 2011-08-01 2019-09-26 Genentech Inc Antagonistas de unión al eje pd-1e inhibidores de mek y sus usos en el tratamiento de cáncer.
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
CN114380700A (zh) * 2013-10-08 2022-04-22 卢庆彬 用于靶向化疗的非铂基抗癌化合物
EP3563870A1 (de) 2014-07-15 2019-11-06 F. Hoffmann-La Roche AG Verfahren zur behandlung von krebs unter verwendung von pd-1-achsen-bindenden antagonisten und mek-inhibitoren
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
KR19990012061A (ko) 1997-07-26 1999-02-25 성재갑 파네실 전이효소 저해제로 유용한 하이덴토인 유도체
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ES2331246T3 (es) * 2003-07-24 2009-12-28 Warner-Lambert Company Llc Derivados de benzamidazol como inhibidores del mek.
US20070191444A1 (en) * 2004-02-26 2007-08-16 Hans-Peter Buchstaller Benzimidazolyl derivatives
BRPI0514515A (pt) * 2004-08-17 2008-06-10 Hoffmann La Roche hidantoìnas substituìdas
TW200621766A (en) * 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
WO2006124780A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
US7612212B2 (en) * 2006-02-22 2009-11-03 Hoffmann-La Roche Inc. Substituted hydantoins

Also Published As

Publication number Publication date
WO2009021887A1 (en) 2009-02-19
MX2010001581A (es) 2010-03-15
JP2010536723A (ja) 2010-12-02
AU2008288556A1 (en) 2009-02-19
KR20100031777A (ko) 2010-03-24
CN101778839A (zh) 2010-07-14
US7557221B2 (en) 2009-07-07
EP2188276A1 (de) 2010-05-26
ES2383927T3 (es) 2012-06-27
EP2188276B1 (de) 2012-03-28
BRPI0815180A2 (pt) 2019-09-24
CA2695956A1 (en) 2009-02-19
KR101147583B1 (ko) 2012-05-21
US20090048452A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
ATE551336T1 (de) Substituierte hydantoine
EA200970557A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
MA32508B1 (fr) Composes organiques
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
MA26351A1 (fr) Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta+lactamases
EA201100687A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
EA200800664A1 (ru) Производные пирролопиримидина в качестве ингибиторов syk
NO20082482L (no) Karbonylamino pyrrolpyrazoler, samt anvendelse som kinase inhibitorer
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
EA200800201A1 (ru) Кристаллические формы 4-метил-n-[3-(4-метилимидазол-1-ил)-5-трифторметилфенил]-3-(4-пиридин-3-илпиримидин-2-иламино)бензамида
EA201100450A1 (ru) Макроциклические пирамидины в качестве ингибиторов протеинкиназы
EA200700220A1 (ru) Имидазотриазины в качестве ингибиторов протеинкиназы
WO2006120573A3 (en) Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
NO20070557L (no) Ftalazinderivater som PARP-inhibitorer
EA200970738A1 (ru) Ингибиторы активности akt
EA200901483A1 (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНА И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
IS6501A (is) Pyrrólafleiður 2-indólínón prótín kínasa hindra
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
EA200700142A1 (ru) Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
ECSP088121A (es) Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
ATE554087T1 (de) Neue kinaseinhibitoren
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины